Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

Arena Shares Plunge after Disappointing First Quarter Results

By Pharmaceutical Processing | May 2, 2013

Arena Pharmaceuticals Inc. said Thursday that its loss narrowed in the first quarter, though company executives said they are still waiting for a federal decision on the status of the weight loss drug Belviq.

The Food and Drug Administration approved Belviq on June 27, but the drug has not gone on sale yet. The Drug Enforcement Administration is proposing that Belviq be classified as a Schedule IV controlled substance, which means it has a relatively low potential for abuse. Arena and its partner Eisai Co. can’t start marketing Belviq until that classification is approved. It’s not clear when that will happen.

“We look forward to the completion of Belviq’s scheduling designation in the United States, and we are focused on making this new treatment option available to patients in additional parts of the world,” said Jack Lief, Arena’s president and CEO.

Company shares fell $1.27, or 15.1 percent, to $7.13 in after-hours trading. The stock closed earlier in the day up 2 percent to $8.40.

Belviq, or lorcaserin, is designed to stimulate serotonin receptors in the brain linked with feelings of satiety, leading patients to feel full. It was one of two new prescription weight loss drugs approved by the FDA last year, along with Vivus’ Qsyimia. That drug went on sale in September. The FDA hadn’t previously approved a new weight-loss prescription since 1999.

Arena said it lost $18.9 million, or 9 cents per share, compared with $29.4 million, or 18 cents per share, a year earlier. Arena sold more than 70 million new shares of stock in 2012, which is reflected in the per-share results of the last quarter.

Revenue edged up to $2.37 million from $2.2 million. The company posted $500,000 from a milestone payment from Eisai for filing Belviq for approval in Mexico.

Analysts polled by FactSet expected earnings of 20 cents per share on revenue of $68.3 million. On average, analysts expected the company to record $67.2 million in milestone payments tied to the launch of Belviq, according to FactSet. Arena is scheduled to receive payments after Belviq is scheduled by DEA regulators and inventory ships to its partner Eisai.

Related Articles Read More >

This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
sherwin-williams-pharma-facility (1)
Sherwin-Williams expands flooring solutions for pharma facilities
PHARMAP 2025: Pharma leaders converge in Berlin for fifth anniversary summit
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE